Illumina (NASDAQ:ILMN) received a $372.00 price objective from research analysts at Argus in a research note issued to investors on Friday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the life sciences company’s stock. Argus’ target price would indicate a potential upside of 12.64% from the stock’s current price.

A number of other research firms also recently commented on ILMN. Morgan Stanley upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and boosted their target price for the stock from $210.00 to $320.00 in a report on Tuesday, August 7th. ValuEngine upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 31st. JPMorgan Chase & Co. boosted their target price on shares of Illumina to $350.00 and gave the stock an “overweight” rating in a report on Tuesday, July 31st. Bank of America boosted their target price on shares of Illumina from $345.00 to $370.00 and gave the stock a “buy” rating in a report on Tuesday, July 31st. Finally, Piper Jaffray Companies boosted their target price on shares of Illumina from $272.00 to $329.00 and gave the stock an “overweight” rating in a report on Tuesday, July 17th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $303.53.

Shares of Illumina traded down $3.25, reaching $330.25, during midday trading on Friday, according to Marketbeat. The company’s stock had a trading volume of 894,676 shares, compared to its average volume of 1,105,790. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.44. Illumina has a one year low of $189.15 and a one year high of $341.08. The company has a market capitalization of $49.02 billion, a P/E ratio of 82.56, a PEG ratio of 2.79 and a beta of 0.97.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.32. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The business had revenue of $830.00 million for the quarter, compared to the consensus estimate of $786.88 million. During the same period in the previous year, the firm earned $0.82 EPS. The business’s revenue for the quarter was up 25.4% on a year-over-year basis. analysts anticipate that Illumina will post 5.41 earnings per share for the current year.

In other news, EVP Omead Ostadan sold 1,335 shares of the business’s stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $274.61, for a total transaction of $366,604.35. Following the sale, the executive vice president now owns 25,818 shares in the company, valued at $7,089,880.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert S. Epstein sold 500 shares of the business’s stock in a transaction that occurred on Thursday, June 21st. The shares were sold at an average price of $288.45, for a total transaction of $144,225.00. Following the sale, the director now owns 6,639 shares in the company, valued at approximately $1,915,019.55. The disclosure for this sale can be found here. Insiders have sold 46,941 shares of company stock worth $13,293,834 in the last 90 days. 0.54% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in ILMN. Jennison Associates LLC increased its stake in Illumina by 4.5% in the 2nd quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock valued at $1,200,271,000 after buying an additional 185,745 shares during the period. Fred Alger Management Inc. increased its stake in Illumina by 21.4% in the 2nd quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock valued at $217,413,000 after buying an additional 137,302 shares during the period. Prudential Financial Inc. increased its stake in Illumina by 75.9% in the 1st quarter. Prudential Financial Inc. now owns 762,186 shares of the life sciences company’s stock valued at $180,196,000 after buying an additional 328,886 shares during the period. American Century Companies Inc. increased its stake in Illumina by 19.2% in the 1st quarter. American Century Companies Inc. now owns 761,796 shares of the life sciences company’s stock valued at $180,104,000 after buying an additional 122,612 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in Illumina by 5.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock valued at $168,863,000 after buying an additional 31,985 shares during the period. Institutional investors and hedge funds own 90.31% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.